Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is committed to accelerating the research and discovery of the target CSF1R by providing recombinant products that exemplify the highest quality standards. Our offerings not only deliver exceptional value but also come with top-notch technical support to ensure researchers can effectively utilize our products in their studies. By focusing on CSF1R, we aim to empower scientists in their efforts to explore this critical target, ultimately contributing to advancements in understanding and treating related diseases.
The target CSF1R (colony-stimulating factor 1 receptor) is a crucial protein in biological systems. CSF1R is mainly involved in regulating the survival, proliferation, and differentiation of cells such as macrophages. Research on CSF1R is of great significance. It can help us understand the mechanisms of immune responses and inflammatory processes. By targeting CSF1R, scientists can develop new therapeutic strategies for diseases related to abnormal macrophage activation, such as certain autoimmune diseases and cancer. Studying CSF1R also provides insights into the development and function of the immune system, potentially leading to the discovery of novel treatments for a variety of disorders.
Colony stimulating factor 1 receptor; FMS; CSFR; FIM2; GPSC; HDLS; C-FMS; CD115; HDLS1; CSF-1R; BANDDOS; M-CSF-R
The protein encoded by this gene is the receptor for colony-stimulating factor 1, a cytokine that controls the production, differentiation, and function of macrophages. This receptor mediates most if not all the biological effects of this cytokine. Ligand binding activates the receptor kinase through a process of oligomerization and transphosphorylation. The encoded protein is a tyrosine kinase transmembrane receptor and a member of the CSF1/PDGF receptor family of tyrosine-protein kinases. Mutations in this gene have been associated with a predisposition to myeloid malignancy. The first intron of this gene contains a transcriptionally inactive ribosomal protein L7 processed pseudogene oriented in the opposite direction. Alternative splicing results in multiple transcript variants. Expression of a splice variant from an LTR promoter has been found in Hodgkin lymphoma (HL), HL cell lines, and anaplastic large cell lymphoma.
Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, RAS pathway related proteins
Intracellular, Membrane (different isoforms)
Cell type enhanced (Hofbauer cells, Kupffer cells, Macrophages, Microglial cells, Extravillous trophoblasts, Langerhans cells)
Immune cell enhanced (non-classical monocyte, intermediate monocyte)
Group enriched (BEWO, SK-BR-3)
Interacts with INPPL1/SHIP2 and THOC5 (By similarity). Monomer. Homodimer. Interacts with CSF1 and IL34. Interaction with dimeric CSF1 or IL34 leads to receptor homodimerization. Interacts (tyrosine phosphorylated) with PLCG2 (via SH2 domain). Interacts (tyrosine phosphorylated) with PIK3R1 (via SH2 domain). Interacts (tyrosine phosphorylated) with FYN, YES1 and SRC (via SH2 domain). Interacts (tyrosine phosphorylated) with CBL, GRB2 and SLA2.
Kinase, Receptor, Transferase, Tyrosine-protein kinase
We provide high-quality and excellent antibody products to fulfill the research needs of a diverse group of researchers about the target CSF1R and its functions.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-H23 | Anti-Human CSF1R Recombinant Antibody (Emactuzumab) | Human | Human | WB; ELISA; IP; FC; FuncS; Neut; IF |
TAB-303LC | Human Anti-CD47 Recombinant Antibody | Human | Human | ELISA |
TAB-011ML | Anti-Human CSF1R Recombinant Antibody (Cabiralizumab) | Human | Human | ELISA; IHC; FC; IP; IF; Inhib |
HPAB-0574-CN | Mouse Anti-CSF1R Recombinant Antibody | Human | Mouse | ELISA; Block |
HPAB-0579-CN | Human Anti-CSF1R Recombinant Antibody | Human; Monkey | Human | ELISA; FC; Neut |
To satisfy our customers' requirements, we have instituted a set of stringent quality management systems throughout the production process of antibody products to guarantee their high quality.
Fig.1 SDS-PAGE analysis of anti-CSF1R antibody
(Cat# TAB-H23, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CSF1R antibody
(Cat# TAB-H23, Creative Biolabs).
Fig.3 WB analysis of anti-CSF1R antibody
(Cat# TAB-H23, Creative Biolabs).
Fig.4 ELISA analysis of anti-CSF1R antibody
(Cat# TAB-H23, Creative Biolabs).
Fig.5 DB analysis of anti-CSF1R antibody
Cat# TAB-H23, Creative Biolabs).
Creative Biolabs provides one-stop services covering everything from gene synthesis to the production of high-quality recombinant antibodies. As a result, we can offer customers excellent antibody production services.
Featured Anti-CSF1R Recombinant Antibody Production Platforms
Fig.6 Milligram-scale recombinant antibody production.
Fig.7 Gram-scale recombinant antibody production.
Creative Biolabs is dedicated to supplying researchers with a wide range of high-quality recombinant antibodies in diverse formats that are both comprehensive and state-of-the-art. This enables researchers to meet their various research requirements and saves them time and effort.
Fig.8 Full Length Anti-CSF1R Recombinant Antibody Production and Modalities.
Table 1. Therapeutic approaches targeting CSF1R in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2022 | Baxalta | Small Molecules |
Acute myeloid leukemia; Cancer |
It is an orally available kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, developed by CTI Biopharma (formerly Cell Therapeutics). |
Launched - 2021 | Hutchison China MediTech | Small Molecules | Cancer | This is an oral angio-immuno kinase inhibitor targeting FGFR1, CSF-1R and all three subtypes of VEGF receptors developed by HUTCHMED. |
Launched - 2019 | Daiichi Sankyo | Small Molecules | Acute myeloid leukemia; Cancer | It is an oral small molecule CSF-1R inhibitor, originally developed at Pelxxikon. |
Launched - 2019 | Ambit Biosciences | Small Molecules |
Acute myeloid leukemia; Cancer |
This is an angiogenesis inhibitor targeting FLT3, KIT, CSF1R/FMS, RET and PDGFR developed by Ambit Biosciences (now Daiichi Sankyo), was first launched in Japan in 2019 for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). |
Launched - 2006 | Bristol-Myers Squibb | Small Molecules | Acute lymphocytic leukemia | It is a highly potent, small-molecule Src kinase and Bcr-Abl kinase inhibitor developed at Bristol-Myers Squibb, was launched in the U.S. in 2006 for the treatment of chronic myelogenous leukemia (CML) in chronic, accelerated or blast phase and the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). |
Launched - 2006 | CalciMedica | Small Molecules | Acute myeloid leukemia | This is an orally active, multitargeted tyrosine kinase inhibitors originally developed by Sugen and acquired by Pfizer following Pfizer's acquisition of Pharmacia in 2003. |
Launched - 2001 | Aerami Therapeutics | Small Molecules |
Acute lung injury; Acute lymphocytic leukemia |
It was first launched in 2001 as Gleevec(TM) tablets by originator Novartis for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the blast crisis, accelerated phase or in chronic phase after failure of interferon-alpha therapy. |
Pre-Registered | Handa Pharmaceuticals | Small Molecules | Chronic myeloid leukemia | It is being developed at Handa Pharmaceutical using its ONCORE(TM) technology for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. |
Pre-Registered | Incyte | Biologics | Cancer | This is a humanized monoclonal antibody against the macrophage colony-stimulating factor 1 receptor (CSF-1R) being jointly developed by Syndax Pharmaceuticals and Incyte. |
Phase III | Abbisko Therapeutics | Small Molecules |
Amyotrophic lateral sclerosis; Cancer |
It is an oral, small-molecule CSF-1R inhibitor in phase III clinical development at Abbisko Therapeutics for the treatment of unresectable tenosynovial giant cell tumors (TGCT), and in phase II clinical development for chronic graft-versus-host disease (cGVHD) and advanced pancreatic cancer. |
Phase III | Nanjing TransThera Biosciences | Small Molecules | Cancer | This is an oral, small-molecule multi-targeted kinase inhibitor in phase III clinical development at Nanjing TransThera Biosciences for the treatment of cholangiocarcinoma. |
Phase III | Chiesi | Small Molecules | Hypertension, pulmonary | It is a small-molecule kinase inhibitor active against the PDGFRalpha/beta, CSF1R and c-KIT kinases in phase III clinical development at Gossamer Bio as an inhaled treatment for pulmonary arterial hypertension. |
Phase III | Deciphera | Small Molecules | Cancer | This is an oral, small-molecule switch-control inhibitor of CSF1R in phase III clinical development at Deciphera as a treatment for tenosynovial giant cell tumors, either localized or diffuse. It is also undergoing phase I/II clinical evaluation in patients with advanced solid tumors. |
Phase III | Celleron Therapeutics | Biologics | Cancer | It is a humanized anti-CSF-1R monoclonal antibody in phase III clinical development at SynOx Therapeutics for the treatment of patients with localized or diffuse tenosynovial giant cell tumors (TGCT). |
Phase III | Abbott | Small Molecules | Cancer | This is a novel orally active receptor tyrosine kinase (RTK) inhibitor that had been in development at Abbvie for the treatment of leukemia. |
If you need more detailed information on anti-CSF1R recombinant antibody products, please don't hesitate to contact us. Our team is enthusiastic about providing the assistance you need and is eager to establish a beneficial and productive partnership that advances your research goals.